Abstract
It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children. This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity. Eighteen boys with obesity were treated with recombinant human growth hormone for one year. Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively. After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased (P < 0.001) and insulin-like growth factor 1 levels increased (P < 0.001). GH treatment also reduced low density lipoprotein cholesterol (P < 0.001), total cholesterol (P < 0.001), triglycerides (P=0.042), and alanine aminotransferase (P=0.027) when compared with the baseline. One-year of recombinant human growth hormone treatment could improve cardiometabolic risk markers, without adverse effects on glucose homeostasis in boys with obesity.
Highlights
As obesity has become more and more popular, many people are plagued by the comorbidities associated with obesity [1]
We reported that 6 months of growth hormone (GH) treatment reduced body mass index standard deviation scores (BMI SDS), exerting beneficial effects on blood lipid profiles without causing deterioration on glucose homeostasis in obese children with relative GH deficiency [21]
We examine the effect of one year of recombinant human growth hormone (rhGH) on cardiometabolic risk factors in otherwise healthy boys with obesity. e results show that one year of GH treatment reduced the BMI SDS and ALT, raised insulin-like growth factor 1 (IGF-1) levels, and improved the serum lipid pattern
Summary
As obesity has become more and more popular, many people are plagued by the comorbidities associated with obesity [1]. Obesity and obesity-related comorbidities, have been identified as one of the most important public health concerns in the world [1]. Erefore, more and more studies started to focus on the relevant topics related to obesity and its complications. Apart from obesity-related comorbidities, obesity is associated with endocrine perturbations. Low growth hormone (GH) secretion has been recognized as one of their characteristics [4, 5]. Several studies indicated that GH secretion was negatively associated with cardiovascular complications in obese adults [7,8,9,10,11]. Our previous studies confirmed the abnormalities of the GH/insulin-like growth factor 1 (IGF-1) axis
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
